ArticleFrontiers in public health2026
Temporal changes in allergen-specific IgE sensitization patterns in Xiamen, 2019-2023: a retrospective cross-sectional analysis.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic has induced substantial changes in environment, lifestyle, and health behaviors. We observed temporal associations between the pandemic period and declining sIgE positivity rates; however, causality cannot be established due to the retrospective observational design. Distinguishing between asymptomatic sensitization (positive specific IgE without clinical symptoms) and true allergic disease remains critical. This study aims to describe the trends in allergen-specific IgE (sIgE) positivity-as a marker of sensitization-in the Xiamen population from 2019 to 2023, a surrogate marker of sensitization that does not equate to clinical allergy, providing insights into population-level immunological changes during the pandemic. Methods: We performed a retrospective cross-sectional analysis of 3,207 serum sIgE testing records (3,210 initial records minus 3 exclusions) from patients who underwent allergen screening at our hospital between January 2019 and December 2023. These records include repeated tests from some individuals; a subset of 2,784 records from 2,750 unique patients was used for GEE modeling to account for within-individual correlation. Data on sensitization to inhalant allergens (e.g., dust mites, cat dander, cockroach) and food allergens (e.g., egg white, crab, milk) were analyzed. Age and sex distributions were examined, though detailed information on clinical symptoms (e.g., eczema, rhinitis), comorbidities, and longitudinal follow-up of individual patients was not available. Results: Among 3,207 testing records, 1,454 (45.34%) were positive for sIgE to one or more allergens. The annual positivity rate declined sharply from 76.07% (89/117) in 2019 to 32.26% (519/1,609) in 2023 ( Conclusion: This study documents a significant decline in sIgE positivity rates for both inhalant and food allergens in Xiamen from 2019 to 2023. To our knowledge, this is the first report from Xiamen spanning the full COVID-19 pandemic period, providing foundational data for future hypothesis-driven research. Sex- and age-specific differences in sensitization patterns were observed. However, based on the current dataset alone, it is not possible to determine whether these changes reflect true shifts in clinical allergic disease or result from alterations in testing practices, population composition, or other confounders. Future research must integrate detailed clinical phenotyping (including age-stratified symptom data, comorbidities such as eczema, and longitudinal follow-up) and lifestyle/environmental measurements to identify modifiable factors for preventing allergy development-not merely managing sensitization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.